Quick Answer
Climb Bio, Inc. reported Total Assets of $167.74 million for the year ending 2025.
- Climb Bio, Inc. showed a decrease of -22.8% in Total Assets from 2024 to 2025.
- This data is from Climb Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $107.63 million | Q3 2021: $182.25 million | Q1 2022: $162.42 million | Q2 2022: $150.11 million | Q3 2022: $140.86 million | Q1 2023: $122.09 million | Q2 2023: $116.27 million | Q3 2023: $112.74 million | Q1 2024: $109.33 million | Q2 2024: $226.02 million | Q3 2024: $222.20 million | Q1 2025: $200.74 million | Q2 2025: $192.39 million | Q3 2025: $182.30 million.
- Over the full 6 years of available data (2020 to 2025), Climb Bio, Inc.'s Total Assets has grown by 581.0%.
- Historical annual values: Fiscal year 2025: $167.74 million | Fiscal year 2024: $217.19 million | Fiscal year 2023: $110.47 million | Fiscal year 2022: $134.99 million | Fiscal year 2021: $173.24 million | Fiscal year 2020: $24.63 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: